Related Experiment Videos
Lipoprotein (a) in Behçet's disease as an indicator of disease activity and in thrombotic complications
Insights
Plasma lipoprotein (a) (Lp(a)) levels indicate Behçet
Area of Science:
- Rheumatology
- Immunology
- Cardiovascular Research
Background:
- Behçet's disease is a chronic inflammatory disorder with potential thrombotic complications.
- Lipoprotein (a) (Lp(a)) is a modified lipoprotein particle implicated in cardiovascular disease.
- The role of Lp(a) in Behçet's disease activity and thrombotic events requires further elucidation.
Purpose of the Study:
- To assess plasma Lp(a) concentrations as a marker for Behçet's disease activity.
- To investigate the association between Lp(a) levels and thrombotic complications in Behçet's disease.
Main Methods:
- A case-control study comparing 30 Behçet's disease patients (active and inactive) with 30 healthy controls.
- Clinical assessment of disease activity and measurement of plasma Lp(a), C-reactive protein (CRP), C3, and C4.
- Analysis of Lp(a) levels in relation to disease activity and history of thrombotic events.
Main Results:
- Significantly elevated plasma Lp(a) and acute phase reactant levels in Behçet's disease patients compared to controls.
- Higher Lp(a) concentrations observed during active Behçet's disease compared to inactive phases.
- Lp(a) levels correlated with other acute phase reactants but showed no association with thrombotic complications in inactive disease.
Conclusions:
- Plasma Lp(a) may serve as a valuable indicator of disease activity in Behçet's disease.
- No correlation found between Lp(a) levels and thrombotic sequelae in inactive Behçet's disease.
- Further research is warranted to explore the thrombogenic role of Lp(a) during active Behçet's disease, particularly in thrombophlebitis.
Purpose:
To evaluate the utility of plasma concentrations of lipoprotein (a) (Lp(a)) as an indicator of disease activity in Behçet's disease and to investigate its role in thrombotic complications of this disease.
Methods:
30 patients (19 male, 11 female) with Behçet's disease (8 active, 22 inactive) were enrolled in the study group and 30 healthy individuals (16 male, 14 female) in the control group. Seven of the inactive Behçet's disease patients had a history of thrombotic complications. The disease activity was evaluated by clinical manifestations (oral aphthous lesions, genital ulcerations, uveitis and vasculitis) and laboratory investigations (leucocyte count, lipoprotein (a), C-reactive protein (CRP), complement 3 (C3) and complement 4 (C4) concentrations).
Results:
Plasma Lp(a) and other acute phase reactant concentrations were significantly higher in the study group than in the controls (p < 0.01). These concentrations were also higher during the active period of the disease than during the inactive phase (p < 0.01). Lp(a) concentrations were significantly correlated with concentrations of other acute phase reactants. There was no difference between the groups with and without thrombotic complications for any of these measurements. CONCLUSIONS. Plasma levels of Lp(a) might be an indicator of disease activity in Behçet's disease. There is no correlation between Lp(a) levels and thrombotic sequela in inactive Behçet's disease. However, further studies are needed on the thrombogenic role of Lp(a) during the active phase of thrombophlebitis, and in larger series.